Vor Biopharma (VOR) Equity Average (2020 - 2026)
Vor Biopharma (VOR) reported Equity Average of -$157.4 million for Q1 2026, down 928.72% year-over-year from $19.0 million in Q1 2025, and up 86.83% on a QoQ basis from -$1.2 billion in Q4 2025.
Vor Biopharma (VOR) has 7 years of Equity Average data on file, last reported at -$157.4 million in Q1 2026.
- Quarterly Equity Average fell 928.72% year-over-year to -$157.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$157.4 million (down 928.72% YoY) and the FY2025 annual result came in at -$130.5 million, down 582.75% from the prior year.
- Equity Average improved to -$157.4 million in Q1 2026 per VOR's latest filing, from -$1.2 billion in the prior quarter.
- Across five years, Equity Average topped out at $240.4 million in Q1 2023 and bottomed at -$1.9 billion in Q3 2025.
- The 5-year median for Equity Average is $136.9 million (2024), against an average of -$121.2 million.
- The widest annual swing landed in 2022, when Equity Average soared 97.34%; it then tumbled 9979.71% in 2025.
- Tracing VOR's Equity Average over 5 years: stood at $204.7 million in 2022, then fell by 20.48% to $162.8 million in 2023, then sank by 107.28% to -$11.9 million in 2024, then plunged by 9979.71% to -$1.2 billion in 2025, then jumped by 86.83% to -$157.4 million in 2026.
- Per Business Quant, the three latest VOR Equity Average figures stand at -$157.4 million (Q1 2026), -$1.2 billion (Q4 2025), and -$1.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -157.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.37 Mn |
| Dec 31, 2025 | -1.19 Bn |
| Sep 30, 2025 | -1.87 Bn |
| Jun 30, 2025 | -719.82 Mn |
| Mar 31, 2025 | -15.30 Mn |
| Dec 31, 2024 | -11.85 Mn |
| Sep 30, 2024 | 85.52 Mn |
| Jun 30, 2024 | 110.56 Mn |
| Mar 31, 2024 | 136.88 Mn |
| Dec 31, 2023 | 162.75 Mn |
| Sep 30, 2023 | 189.62 Mn |
| Jun 30, 2023 | 217.33 Mn |
| Mar 31, 2023 | 240.41 Mn |
| Dec 31, 2022 | 204.67 Mn |
| Sep 30, 2022 | 166.85 Mn |
| Jun 30, 2022 | 184.71 Mn |
| Mar 31, 2022 | 205.36 Mn |
| Dec 31, 2021 | 224.61 Mn |
| Sep 30, 2021 | 241.53 Mn |
| Jun 30, 2021 | 258.65 Mn |
| Mar 31, 2021 | 104.06 Mn |
| Dec 31, 2020 | -51.60 Mn |
| Sep 30, 2020 | -38.57 Mn |
| Jun 30, 2020 | -29.06 Mn |